State OR
Clinical Trials in Oregon
Recruiting clinical trials with at least one study location in Oregon. Data updated daily from ClinicalTrials.gov.
Top Conditions in Oregon
Malignant Solid Neoplasm (5)Advanced Solid Tumor (5)Prostate Cancer (4)Acute Myeloid Leukemia (4)Parkinson Disease (4)Myeloproliferative Neoplasm (3)Hematopoietic and Lymphatic System Neoplasm (3)Acute Lymphoblastic Leukemia (3)Atopic Dermatitis (3)Breast Cancer (3)Acute Respiratory Distress Syndrome (3)NSCLC (Non-small Cell Lung Cancer) (3)
NCT07221149 Phase 2, Phase 3
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Che...
Condition
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Enrollment
690 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT06353243 N/A
Recruiting
Bilateral Infant Stimulation Study
Condition
Parent-Child Relations
Enrollment
40 pts
Location
United States
Sponsor
Oregon Health and Science Univ
NCT05813678 N/A
Recruiting
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALac...
Condition
Phenylketonuria (PKU)
Enrollment
450 pts
Location
United States, Germany, Italy
Sponsor
BioMarin Pharmaceutical
NCT06070350 Phase 3
Recruiting
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage...
Condition
Hemorrhagic Shock
Enrollment
1,000 pts
Location
United States
Sponsor
Philip Spinella
NCT05591118 Phase 3
Recruiting
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
Condition
Pulmonary Embolism
Enrollment
500 pts
Location
United States
Sponsor
NYU Langone Health
NCT05382338 Phase 3
Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hear...
Condition
Childhood Medulloblastoma
Enrollment
225 pts
Location
United States, Canada
Sponsor
Children's Oncology Group
NCT03373968 Phase 2, Phase 3
Recruiting
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability St...
Condition
Duchenne Muscular Dystrophy
Enrollment
206 pts
Location
United States, Belgium, Canada
Sponsor
Italfarmaco
NCT06381674 N/A
Recruiting
Wearable Technology to Characterize and Treat mTBI Subtypes: Biofeedback-Based P...
Condition
Mild Traumatic Brain Injury, Concussion
Enrollment
100 pts
Location
United States
Sponsor
Oregon Health and Science Univ
NCT02432625 N/A
Recruiting
BBD Longitudinal Study of Osteogenesis Imperfecta
Condition
Osteogenesis Imperfecta
Enrollment
1,000 pts
Location
United States, Canada
Sponsor
Baylor College of Medicine
NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5...
Condition
Advanced Solid Tumor
Enrollment
300 pts
Location
United States, Australia, France
Sponsor
PMV Pharmaceuticals, Inc
NCT07449923 Phase 3
Recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1...
Condition
Diabetic Macular Edema
Enrollment
240 pts
Location
United States
Sponsor
EyePoint Pharmaceuticals, Inc.
NCT06773962 Phase 2
Recruiting
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's ...
Condition
Parkinson's Disease (PD)
Enrollment
62 pts
Location
United States
Sponsor
TrueBinding, Inc.
NCT05873686 Phase 1
Recruiting
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Condition
Advanced Solid Tumor
Enrollment
140 pts
Location
United States, United Kingdom
Sponsor
Nuvectis Pharma, Inc.
NCT05818189 N/A
Recruiting
Cortical Correlates of Gait in Parkinson's Disease: Impact of Medication and Cue...
Condition
Parkinson Disease
Enrollment
60 pts
Location
United States
Sponsor
Oregon Health and Science Univ
NCT07265479 Phase 3
Recruiting
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participant...
Condition
Atopic Dermatitis
Enrollment
180 pts
Location
United States, Canada
Sponsor
Organon and Co
NCT03739827 N/A
Recruiting
Natural History and Biospecimen Acquisition for Children and Adults With Rare So...
Condition
Malignant Solid Tumors
Enrollment
10,000 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT06940674 Phase 3
Recruiting
Adjunctive Cannabidiol for Recovery From Opioid Study
Condition
Opioid Use Disorder (OUD)
Enrollment
450 pts
Location
United States
Sponsor
Icahn School of Medicine at Mo
NCT05444582 Phase 4
Recruiting
Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start
Condition
Contraception
Enrollment
1,404 pts
Location
United States
Sponsor
University of Utah
NCT06357676 Phase 1, Phase 2
Recruiting
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With M...
Condition
Mantle Cell Lymphoma
Enrollment
27 pts
Location
United States
Sponsor
OHSU Knight Cancer Institute
NCT06567743 Phase 2
Recruiting
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec ...
Condition
High-Risk Non-Muscle-Invasive Bladder Cancer
Enrollment
325 pts
Location
United States
Sponsor
CG Oncology, Inc.
NCT05543616 Phase 2, Phase 3
Recruiting
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Heal...
Condition
SARS-CoV-2 Virus
Enrollment
4,292 pts
Location
United States, Brazil, Puerto Rico
Sponsor
BioNTech SE
NCT07166406 Phase 3
Recruiting
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Pat...
Condition
Advanced Hepatocellular Carcinoma
Enrollment
252 pts
Location
United States
Sponsor
NRG Oncology
NCT04811560 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Condition
Acute Leukemias
Enrollment
400 pts
Location
United States, Australia, Brazil
Sponsor
Janssen Research & Development
NCT06339008 Phase 3
Recruiting
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (...
Condition
Perennial Allergic Rhinitis (PAR)
Enrollment
450 pts
Location
United States, Belgium, China
Sponsor
Eli Lilly and Company
NCT06667076 Phase 2
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combina...
Condition
Carcinoma, Non-Small-Cell Lung
Enrollment
480 pts
Location
United States, Belgium, Finland
Sponsor
Janssen Research & Development